Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1720-1726

  Rothenberg, M L ^a   Cox, J V ^b   Butts, C ^c   Navarro, M ^d   Bang, Y J ^e   Goel, R ^f   Gollins, S ^g   Siu, L L ^h   Laguerre, S ⁱ   Cunningham, D ^j  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

^d HOSPITAL DURAN I REYNALS   (Spain)

^e Seoul National University Hospital   (South Korea)

^f UNIVERSITY OF OTTAWA   (Canada)

^g GLAN CLWYD HOSPITAL   (United Kingdom)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

5 fluorouracil folinic acid; Capecitabine; FOLFOX 4; Metastatic colorectal cancer; Oxaliplatin; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 53049092394     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn370     Document Type: Article

References (20)

1. Goldberg RM, Rothenberg ML, van Cutsem E et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50.
2. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs Intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190-1197.
4. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
6. Cassidy J, Tabemero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
7. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003: S90 (Abstr 295).
8. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312.
9. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 2006; 24: 1Bs. (Abstr 3510 and slideset).
10. Martoni AA, Pinto C, Fable FD et al. Capecitabine plus oxallplatin (XELOX) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006; 42: 3161-3168.
11. Pfeiffer P, Sorbye H, Ehrsson H et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to innotecan and 5-fluorouracil. Ann Oncol 2006; 17: 252-258.
12. Bomer MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Onool 2002; 20: 1759-1766.
13. Cassidy J, Clarke S, Diaz Rubio E et al. A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
14. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 18s (Abstr 4029).
15. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
16. Therasse P, Arbuck SG, Elsenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Toumigand C. André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
18. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
19. Rothenberg ML, Oza AM, Burger B et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following Irinotecan, 5-FU, and leucovorin. J Clin Oncol 2003: 22 (Abstr 1011).
20. Bennouna J, Ducreux M, Hebbar M et al. Capecitabine + oxaliplatin (XELOX) offers benefits over infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC): preliminary safety findings from a phase III study. Proc Am Soc Clin Oncol GI Cancer Symp 2007: (Abstr 273).